This study is designed to test the safety and potential benefit of adding an existing drug used for bone protection (denosumab) to a new immune stimulating drug (pembrolizumab).
Metastatic kidney cancer
Denosumab and Pembrolizumab in clear cell renal carcinoma: a phase II trial (ANZUP1601) KidnEY cancer Pembrolizumab And Denosumab.
- Kidney Cancer after progression on first line treatment
- No prior treatment with immunotherapy
The treatment is 3 weekly Pembrolizumab and Denosumab. While on treatment there will be regular blood tests and scans to monitor progress. At completion of treatment the study will continue to follow your progress.